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Recombinant DNA technology and protein engineering are creating hope that we can address ongoing chal-
lenges in hemophilia care such as reducing the costs of therapy, increasing the availability to the develop-
ing world, and improving the functional properties of these proteins. Technological advances to improve
the half-life of recombinant clotting factors have brought long-acting clotting factors for hemophilia replace-
ment therapy closer to reality. Preclinical and clinical trial results are reviewed as well as the potential bene-
ﬁts and risks of these novel therapies. Am. J. Hematol. 87:S33–S39, 2012. VC 2012 Wiley Periodicals, Inc.
Introduction
Over the past several decades, clinical care for hemo-
philia has improved dramatically [1] (Fig. 1). The develop-
ment of FVIII and FIX concentrates that can stop or pre-
vent bleeding episodes has reduced the associated morbid-
ity, as well as improved the quality of life and normalized
life expectancy [2]. Regular, long-term prophylactic therapy
with factor concentrates prevents recurrent hemarthroses
and reduces or prevents the development of hemophilic ar-
thropathy [3,4]. This is now the standard of care for the
management of children with hemophilia and is increasingly
being applied in adult care. Comprehensive hemophilia
centers, the adoption of home therapy, and worldwide ad-
vocacy efforts are improving health and quality of life
throughout the world [5]. Advancements in biotechnology
contributed signiﬁcantly through the development of
improved pathogen screening, viral inactivation techniques,
and the development of recombinant versions of factors
VIII and IX [6]. The broad adoption of recombinant therapy
throughout the developed world has signiﬁcantly increased
the supply of clotting factor concentrates and helped
advance aggressive therapeutic interventions such as pro-
phylaxis [7,8]. However, this has come at great costs to
governments, medical insurers, and patient’s families with
an estimated annual cost of over $150,000 per patient in
the USA [9,10]. In addition, barriers persist limiting the
adoption and adherence of effective prophylactic therapy,
particularly in the developing world. Standard prophylaxis
regimens (using 25–40 IU/kg of FVIII three times per week
or 50–100 IU/kg of FIX twice per week) are difﬁcult for
some individuals and suboptimal adherence remains a
problem [11]. The development of alloantibodies that inhibit
the activity of infused replacement products also remains a
signiﬁcant complication [12]. Despite recent gene therapy
strategies that are showing new promise that long-term cor-
rective plasma levels may be achieved [13], a cure for
hemophilia has not yet been realized.
Biotechnology has been successful at overcoming similar
barriers in other disease states. Recombinant DNA technol-
ogy and protein engineering remain important platforms to
address ongoing challenges in hemophilia care such as
reducing the costs of therapy, increasing the availability to
the developing world, and improving the functional proper-
ties of these proteins. Long-acting biological therapeutics
are an incremental advance toward overcoming some of
these barriers. Strategies that have been successful for
other therapeutic proteins are now being applied to FVIII
and FIX and include modiﬁcations such as the addition of
polyethylene glycol (PEG) polymers and polysialic acids,
alternative formulation with polyethylene glycol-modiﬁed
liposomes and bioengineered fusion proteins. In addition,
insights into factor VIII structure and function have allowed
targeted modiﬁcations of the protein to increase the dura-
tion of its cofactor activity and reduce its clearance in vivo.
Similar bioengineering efforts have led to promising modiﬁ-
cations to recombinant VIIa, used to treat individuals with
hemophilia and inhibitors. Some of these therapies may
open up alternative delivery routes such as subcutaneous
administration. This manuscript will explore the hope that
these advances in therapeutics for hemophilia may lead to
improved clinical outcomes, and the reality of the preclinical
and clinical results observed, and the potential risks of
adverse effects that will need to be explored in the decades
ahead.
Themes from the Hemophilia Therapeutic Pipeline
Four major themes have appeared in the research and
development pipeline toward new therapeutic agents for
hemophilia: (1) lower cost factor concentrates, (2) non-pro-
tein therapies, (2) novel bypassing agents for hemostatic
control of inhibitors, and (4) half-life extension through bio-
engineering.
Lower cost factor concentrates could be realized simply
through increasing the competitive landscape of therapeutic
options. The Biologics Price Competition and Innovation
Act, which was part of the Patient Protection and Affordable
Care Act signed into law in 2010 enables the Food and
Drug Administration to approve the marketing of biosimilar
biological products based on a single reference biological
product [14]. Such biosimilars could include minor differen-
ces in clinically inactive components provided they exhibit
no ‘‘clinically meaningful differences’’ in terms of safety, pu-
rity, or potency. Biosimilarity would still need to be demon-
strated through analytical studies, animal studies, and a
clinical study. To this end, the pipelines of all of the current
hemophilia therapeutic manufacturers have expanded such
that there may soon be multiple biosimilar options for
recombinant FVIII, FIX, and VIIa. However, it remains likely
that manufacturers will still seek a standard Biologic
License Application for these ‘‘follow-on biologics’’ limiting
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the aggressiveness of pricing [15]. Enhanced expression
systems may also offer a mechanism to produce recombi-
nant proteins at much higher yields than current cell culture
systems [16]. Transgenic animals have also shown promise
as an efﬁcient source of producing abundant recombinant
proteins taking advantage of the high cell density of the
mammary gland of livestock [17]. Proof of principle for
transgenic expression has now been reported for rFIX [18]
and rFVIII [19] and is being investigated to produce rVIIa.
Another novel area of investigation is targeting inhibitors
of coagulation. The primary targets have been tissue factor
pathway inhibitor (TFPI) and activated protein C (APC).
The defective factor Xa generation from the intrinsic tenase
complex, characteristic of hemophilia, can be overcome by
increasing extrinsic factor X (FX) activation as has been
achieved through the use of prothrombin complex concen-
trates and rVIIa in hemophilia with inhibitors. Alternatively,
the extrinsic pathway can also be stimulated by inhibiting
TFPI, the key regulator of the extrinsic pathway. TFPI has
been effectively targeted by antibodies (anti-TFPI) [20] as
well as naturally occurring (fucoidan) [21] and synthetic
inhibitors (aptamers and peptides) of TFPI [22]. Inhibition of
APC could also enhance thrombin generation and has
been targeted by aptamers and RNAi silencing [23].
Novel bypassing agents for managing inhibitors are
under development including bioengineered variants of
rVIIa to be discussed below. Whereas infusion of factor Xa
should be able to bypass the intrinsic pathway (and the
blockade from inhibitors) and promote thrombin generation,
it is rapidly inactivated in plasma by antithrombin and TFPI
resulting in a short plasma half-life. FX circulates as a zym-
ogen and is converted to an active state by proteolysis at a
highly conserved site (R15-I16), followed by a conforma-
tional change. A novel FX variant (FXI16L) is a functional
protease with ‘‘zymogen-like’’ properties such that it is inef-
fectively targeted for inactivation yet retains prothrombinase
activity when assembled with factors Va and prothrombin
on a phospholipid surface. This results in a novel agent
with a prolonged half-life and bypassing activity and has
demonstrated efﬁcacy in murine models [24].
Half-Life Extension Through Bioengineering
The unmet needs in managing hemophilia include reduc-
ing the costs of replacement therapy, improving access to
the developing world, broadening the adoption of and ad-
herence to prophylactic replacement therapy, reducing or
eliminating reliance on central venous access devices, al-
ternative modes of delivery (subcutaneous or oral), and
reduced immunogenicity (reviewed elsewhere [25]). Some
of these challenges could be overcome through biosimilars
and non-protein therapies. Half-life extension of clotting fac-
tors would also be an important step forward as these
would require less frequent dosing to maintain effective
plasma levels reducing the number of venipunctures per
week, perhaps making it easier to adhere to prophylactic
regimens. This could enhance the adoption of prophylaxis
in young infants when venous access is challenging, per-
haps obviating the need for placement of central venous
catheters and make prophylaxis in adults less intrusive. A
long-acting therapeutic with sufﬁcient bioavailability could
make subcutaneous or even oral delivery a reality [26].
Factor VIII
Based on simulations using FVIII half-lives and in vivo
recoveries observed during clinical trials in patients receiv-
ing prophylaxis, half-lives and infusion regimens (interval
between dosing) had the largest effect on predicted FVIII
plasma levels whereas in vivo recovery and dose changes
exhibited smaller effects [27]. Thus, targeting FVIII half-life
extension through bioengineering should have the greatest
impact in achieving long-therapeutic windows with protec-
tive plasma levels. FVIII is commonly prescribed assuming
an average in vivo recovery of 2 IU/dL for each IU/kg dos-
ing and a half-life of approximately 12 hr. Prophylactic regi-
mens have typically been 25–50 IU/kg every other day or
three times per week (Monday, Wednesday, and Friday)
with a goal to maintain trough FVIII levels above 1 IU/dL
[28]. However, large clinical trials in children and adults
have shown that FVIII half-life varies from 6 to 25 hr
between patients [29,30]. Understanding the mechanisms
underlying FVIII clearance and the factors affecting this
half-life variability will help advance the strategies to pro-
long its half-life in vivo.
Following intravenous infusion, the primary determinant
of FVIII residence time in plasma is its non-covalent associ-
ation with von Willebrand factor (VWF), which protects it
from proteolysis and cellular uptake, extending its half-life
from about 2 hr to 12 hr [31]. Pre-infusion VWF levels cor-
relate to some degree with FVIII half-life with lower levels
of VWF observed in blood group O individuals and higher
VWF levels with age [32,33]. With a hemostatic challenge,
thrombin activation releases FVIII from VWF so that it can
exert its procoagulant function. The majority of infused
FVIII is otherwise cleared in the liver through interaction
with a family of low-density lipoprotein receptor-related pro-
teins (LRP) and heparan sulfate proteoglycan receptors
among others [34]. That FVIII clearance may be related to
VWF clearance is supported by data correlating FVIII half-
life and VWF-antigen/VWF-propeptide ratio. Following syn-
thesis and processing, VWF–propeptide is secreted into
plasma at a 1:1 ratio to mature VWF but is cleared inde-
pendently. The VWF/propeptide ratio has been used as a
marker of VWF clearance [35]. In a recent study, FVIII half-
life was best predicted by the VWF/propeptide ratio sug-
gesting that FVIII clearance was more dependent on the
rate of endogenous clearance of VWF rather than the
absolute VWF level [36]. This important aspect of FVIII
clearance provides insight into the limitations to the current
half-life extension strategies.
The ﬁrst strategy to be investigated in clinical trials was
sustained delivery of rFVIII through association with lipo-
somes as a carrier. Because liposomes are typically
cleared very quickly from the circulation, the liposomes
were chemically modiﬁed with PEG to extend their circula-
tory half-life. The rFVIII molecules remain unmodiﬁed so
there is no loss of normal protein–protein interactions
(including rFVIII–VWF interaction) and functional activities.
Preclinical studies within a hemophilia A mouse model
showed that prophylactic infusion of rFVIII reconstituted
with PEGylated liposomes (rFVIII-PEG-Lip) prolonged
some pharmacokinetic parameters compared with standard
Figure 1. Summary of advances in care for hemophilia.
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rFVIII and correlated with an enhanced hemostatic efﬁcacy
[37]. In a blinded, controlled, crossover, multicenter trial, a
single prophylactic infusion of rFVIII-PEG-Lip resulted in a
longer bleed-free interval compared with standard rFVIII
[38]. Despite these promising results, a subsequent double-
blind, randomized, crossover Phase I trial demonstrated
that rFVIII-PEG-Lip and standard rFVIII demonstrated simi-
lar pharmacokinetic parameters [39]. The potential efﬁcacy
of this formulation was most recently investigated in a
randomized, active-controlled, double-blind, prophylaxis trial
in patients with severe hemophilia A comparing once-a-
week dosing of rFVIII-PEG-Lip with three times-per-week
dosing with standard rFVIII [40]. This study was terminated
midstage when interim analysis indicated that the trial
would not meet its efﬁcacy endpoint.
That direct PEGylation of rFVIII hasn’t come to the clinic
sooner may seem surprising, especially since PEGylation
has been successfully applied to a number of biologics to
extend their circulating half-life. PEG polymers incorporate
many water molecules within their hydrophilic structures.
The greatest impact of this for a biologic is to increase the
effective size of the conjugated protein above the ﬁltration
size of the kidney. However, FVIII is already a large glyco-
protein and is not cleared by the kidney; therefore this
increase in effective size is not an advantage. Any advant-
age to PEGylation of FVIII is likely through disruption of
interaction with cellular clearance receptors. Indiscriminate
PEG conjugation could reduce interaction with key activat-
ing proteases or assembly within the tenase complex com-
promising its cofactor function. Alternatively, if PEGylation
reduced FVIII–VWF association, the half-life of FVIII could
be markedly reduced. Both of these observations have
been made since the earliest experimentation with direct
PEGylation of FVIII [41,42]. Advances in chemical conjuga-
tion and innovative bioengineering have allowed for more
precision in selecting the sites for PEG conjugation in order
to avoid interfering with these functional protein–protein
interactions. Mei et al. generated site-speciﬁc PEGylated
rFVIII mutants, achieved through linkage to free surface
exposed cysteine residues introduced through mutagene-
sis, that retained full procoagulant function and VWF bind-
ing in vitro [42]. These conjugates exhibited improved phar-
macokinetics in hemophilic mice and rabbits, and prolonged
efﬁcacy in bleeding models in mice consistent with their
enhanced half-life in vivo. Another site-speciﬁc PEGylation
uses targeted conjugation to an O-linked glycan within a
truncated B domain linker sequence. This also produced an
active molecule which is similar to native FVIIIa. Evaluation
in a hemophilia A dog model demonstrated a close to 2-
fold prolongation of half-life with an accompanying pro-
longed hemostatic effect that would support less frequent
dosing to maintain minimally effective plasma levels [43].
These and similar strategies have been moved forward to
clinical trials (Fig. 2).
An alternative strategy to extend the half-life of biologics
has been to fuse them to another protein with a much lon-
ger half-life. In one example, rFVIII was fused to the con-
stant region (Fc) of immunoglobulin G (rFVIIIFc). Fc-con-
taining proteins that are internalized by endothelial cells
bind to the neonatal Fc receptor (FcRn) present in the
acidiﬁed endosome in a pH-dependent manner and are
then recycled back to the cell surface, avoiding catabolism
in the lysosome, and they are subsequently released back
into plasma at physiologic pH. Preclinical studies with
rFVIIIFc show that in circulation it is complexed with VWF
and released upon activation to exert cofactor activity that
is similar to native FVIII. rFVIIIFc exhibits  2-fold exten-
sion of half-life in hemophilia A mice and dogs [44]. In a
ﬁrst-in-human Phase I study, rFVIIIFc had comparable re-
covery to rFVIII indicating similar afﬁnity for VWF and the
observed half-life was 1.5- to 1.7-fold [45].
In summary, extending the half-life of FVIII has proven to
be challenging. Though these strategies appear to be hav-
ing an impact on the catabolism of FVIII, there has been
continued reliance on VWF association similar to the native
FVIII molecule. This is likely creating a ceiling for the bene-
ﬁt of these approaches of slightly less than 2-fold half-life
extension compared to commercial rFVIII variants.
Factor IX
Though there has been less insight into the mechanisms
of FIX clearance and catabolism, the same strategies that
have been investigated to extend the half-life of FVIII have
had signiﬁcantly more impact on FIX half-life extension.
Recombinant FIX has also been fused to the Fc of immu-
noglobulin G (rFIXFc) and investigated in hemophilia B mice
and dogs [46]. Following intravenous infusion, the half-life of
rFIXFc was 3- to 4-fold longer than rFIX. When infused into
mice deﬁcient in FcRn, the half-life was similar to rFIX sug-
gesting that the enhanced circulatory time is facilitated
through FcRn diverting rFIX away from intracellular degrada-
tion. Within hemophilia B mice, the whole blood clotting time
was corrected through 144 hr for rFIXFc compared to 72 hr
for rFIX. In addition, when the mice were dosed at 200 IU/kg
on days 0, 4, and 8, plasma FIX activity for rFIXFc never
dropped below 0.1 IU/mL (i.e., 10%), whereas mice receiv-
ing rFIX spent the majority of the 4-day interval below 0.1
IU/mL and had trough levels prior to the next dose of <0.01
IU/mL. Within hemophilia B dogs, rFIXFc exhibited a termi-
nal half-life of 47.5 hr compared to previous observations of
17–18 hr for rFIX. In addition, following infusion of 140 IU/
kg, the whole blood clotting time remained corrected to close
to normal levels through 144 hr returning to baseline levels
at 168 hr. The safety and pharmacokinetics of rFIXFc was
subsequently evaluated in previously treated adults with
severe hemophilia B [47]. No serious adverse events related
to the study drug were observed including no inhibitors.
rFIXFc had a half-life that was 3-fold longer than that
reported for rFIX with a mean terminal half-life for FIX activ-
ity of 56.7 hr and a mean residence time of 71.8 hr. Interest-
ingly, the incremental recovery for rFIXFc was similar to
plasma-derived FIX whereas recovery for rFIX has consis-
tently been lower in all prior pharmacokinetic studies [48,49].
Targeted PEGylation of rFIX has also proven to be a suc-
cessful strategy. Given the smaller size of the FIX molecule
with multiple key interactive domains to facilitate its biologic
Figure 2. Long-acting hemophilia therapeutics in the development pipeline. N/A,
not yet available from human clinical trial data.
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activity, indiscriminate PEGylation would risk compromising
its activation from zymogen to protease, interfering with
FVIIIa cofactor activity and/or preventing efﬁcient proteolytic
action on FX. The activation peptide of zymogen FIX is
cleaved off upon activation, liberating it from FIXa. The acti-
vation peptide has two asparagine (N)-linked glycans
which, through innovations in glycoPEGylation, permit tar-
geted enzymatic transfer of 40k PEG [50]. Analysis of the
resultant glycoPEGylated FIX peptides (N9-GP) shows
them to be 95% monoPEGylated with the 40k PEG to be
conjugated roughly equally either to the N-glycan at
Asn157 (55%) or Asn 167 (45%). There is a minor propor-
tion of di-PEGylated FIX. Biochemical characterization of
N9-GP has shown that the activation peptide (that includes
the PEG moieties) is released by physiologic activators
such that the remaining FIXa is unhindered, exhibiting
enzyme kinetics for FX activation that was indistinguishable
from rFIX. Within a 1-stage aPTT assay, the speciﬁc activity
was reduced (73%) compared to rFIX. However, thrombo-
elastography parameters from hemophilic plasma reconsti-
tuted with N9-GP was similar to rFIX. In hemophilia B
dogs, N9-GP has a greatly prolonged half-life of 113 hr
compared to 16 hr for rFIX. Subsequently, the safety and
pharmacokinetics of N9-GP was investigated in 16 previ-
ously treated adults with severe hemophilia B [51]. None of
the subjects developed inhibitors following a single expo-
sure to N9-GP, though one patient developed transient
hypersensitivity symptoms during the administration and
was not included in the pharmacokinetic analysis. In the
remaining 15 patients, N9-GP had a mean half-life of 93 hr,
5-fold higher than rFIX in these patients. Similar to the
observations with rFIXFc, recovery was also markedly
improved with incremental recovery for N9-GP 94% and
20% higher compared to rFIX and plasma-derived FIX,
respectively. In addition, the volume of distribution of N9-
GP was approximately half of that observed for rFIX, sug-
gesting that N9-GP primarily circulates in the blood without
any signiﬁcant tissue distribution.
An additional fusion protein strategy has also advanced
through the pipeline. Albumin has a half-life of 20 days
participating in the same recycling mechanism through
interaction with FcRn as described for immunoglobulin. It
is also an abundant, naturally occurring plasma protein
and has not been shown to be involved in immune
defense reactions, increasing enthusiasm for its suitability
as a fusion partner. Due to the same challenges of avoid-
ing interfering with the regulation of FIX activation and its
protease activity, an innovative fusion strategy was
employed. Recombinant human albumin was fused to rFIX
through a linker sequence that contains a cleavable
sequence identical to the activation site for FIX (rIX-FP)
[52]. Thus, following infusion, rIX-FP would potentially
beneﬁt from the half-life extending properties of albumin,
yet upon activation, albumin and the cleavable linker
would be liberated allowing the resultant FIXa to function
normally. Preclinical studies with rIX-FP have shown that,
depending on the species of animal used, the terminal
half-life was up to 5-fold longer than that of rFIX [53].
Clinical studies have recently been initiated.
Factor VIIa
Although rVIIa has proved to be a safe and effective ther-
apeutic for the management of bleeding in hemophilia
patients with inhibitors, its short plasma half-life requires a
short interval for follow-up dosing and limits its application
in prophylaxis. Clinical studies have suggested that higher
initial doses may result in a more rapid onset of hemostasis
[54,55] and the time from initiation of bleeding to initiation
of treatment may have a signiﬁcant impact on efﬁcacy [56].
In order to overcome these challenges, several bioengin-
eering strategies have been implemented in an attempt to
improve rVIIa functionality: (1) increased potency and rate
of onset of action of rVIIa through directed molecular evolu-
tion and rational design [57,58] and (2) half-life extension
through PEGylation, formulation with PEGylated liposomes,
and fusion proteins to be discussed below. There are also
two N-glycans on the VIIa light chain and protease domains
which can be targeted by glycoPEGylation chemistry. Gly-
coPEGylated rVIIa (N7-GP), is >85% monoPEGylated with
40k PEG and was shown not to change the enzymatic
properties of the molecule such that it could interact efﬁ-
ciently with tissue factor (TF) and activate FX [59]. It also
retained TF-independent thrombin generation on the sur-
face of activated platelets. Safety and pharmacokinetics of
N7-GP were investigated in a Phase I trial in healthy men
[60]. N7-GP exhibited a plasma half-life of 15 hr with meas-
urable activity for up to 72 hr after dosing. However, other
pharmacokinetic properties were also altered. The maxi-
mum FVIIa activity in plasma after administration of 100
ug/kg of N7-GP was 3.8-fold lower than after a 90 ug/kg
dose of rVIIa. In addition, the volume of distribution for N7-
GP was about half of that observed for rVIIa suggesting
N7-GP may circulate primarily in the blood whereas rVIIa is
able to be distributed to surrounding tissues. There were
no thromboembolic complications in the subjects; however,
one blood sample from a single subject was positive for
binding (but non-neutralizing) antibodies to N7-GP and
FVIIa. In a Phase II trial, three different dose levels of N7-
GP were tested in high titer inhibitor patients with hemo-
philia A and B aged 12–65 years [61]. Since this was
designed to also evaluate for efﬁcacy, subjects were eligible
with at least two bleeding episodes per month. Following a
3-month observation period, patients were randomized to
receive 25, 100, or 200 ug/kg of N7-GP every other day for
3 months (treatment period). N7-GP was safe and well-tol-
erated and no antibody formation was detected. Pharmaco-
kinetic determinations were similar to those observed in
subjects within the Phase I trial. The overall reduction in
annualized bleeding frequency across all doses was 44%
comparing the observation period to the treatment period.
However, a dose-response relationship in the bleed reduc-
tion could not be established.
A recombinant FVIIa-albumin fusion protein (rVIIa-FP)
was developed similar to rIX-FP in which rVIIa and
recombinant albumin were joined by a ﬂexible 31-amino-
acid glycine serine linker, which was required to optimize
the potency of the FVIIa [62]. The incremental recovery of
rVIIa-FP was approximately 2-fold higher, and the half-life
was approximately 6-fold longer, than rVIIa in a rat model
[63]. The molar activity for rVIIa-FP was found to be about
70% of that observed for rVIIa and produced a dose-de-
pendent reduction in clotting factor time by ROTEM analy-
sis in an ex vivo inhibitor blood model. These results have
warranted further evaluation in Phase I clinical studies.
Therapeutic Possibilities
Prophylaxis
If there is a benchmark to aim for with respect to clotting
factor replacement therapy for an inherited bleeding disor-
der, factor XIII (FXIII) therapy would be the best achieved
to date. FXIII has a long-circulating half-life of 7–12 days
with full hemostatic activity even at low concentrations. This
allows for routine prophylactic replacement regimens with
dosing intervals of between 4 and 6 weeks [64,65]. Such a
regimen is minimally intrusive even when initiated in infants
and continued through adulthood with high adherence. The
half-life extension strategies for FVIII, FIX, and FVIIa dis-
cussed above still fall short of this, granted lofty, therapeutic
goal. However, if viewed as incremental advances to this
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end, we can speculate on their potential impact and on the
care of patients with hemophilia A and B or those with
inhibitors.
For example, in comparison to a typically prescribed pro-
phylaxis regimen of 25–40 IU/kg of rFIX twice weekly, the
authors used the results from the rFIXFc pharmacokinetic
data to model that once weekly dosing of rFIXFc at 20 IU/
kg, or every 10 days at 40 IU/kg, or even every 2 weeks at
100 IU/kg would be sufﬁcient to maintain a mean trough
level above 1% for patients with severe hemophilia B [47].
Considering the additional beneﬁt of improved incremental
recovery compared to rFIX, this would seem to be a wel-
come advance over current therapeutic strategies. Similarly,
modeling the pharmacokinetic results from N9-GP or rIX-
FP, prophylaxis may be adequate for many patients with
once weekly or less frequent dosing. When the same mod-
eling is applied to the FVIII half-life extension strategies, a
less than 2-fold prolongation of the half-life would likely
mean that patients could move from every other day or
three times per week dosing regimens to twice weekly infu-
sions. However, given the wide range of half-lives observed
in clinical trials, there may be some patients who can
stretch the dosing interval to weekly. The efﬁcacy of these
modiﬁed prophylactic intervals are being explored in the
pivotal trials for these agents. While a prolonged half-life for
rVIIa would advance the application of prophylaxis in
patients with inhibitors, some of the altered pharmacoki-
netic properties and lack of a dose-response relationship in
bleed reduction may temper enthusiasm to advance the
current iteration of glycoPEGylated rVIIa further in clinical
trials. The results from the clinical studies with rVIIa-FP are
not yet available.
On-demand therapy
Even on-demand therapy could be impacted with these
agents. For instance, a longer acting FIX may be able to
arrest bleeding with a single infusion due to an extended
circulating half-life, whereas  20% of bleeding episodes in
hemophilia B require more than a single infusion to achieve
bleed control [66]. This could also be realized for hemo-
philia A management with a longer acting FVIII where not
all bleeds are controlled with a single infusion with current
rFVIII products. In patients with established target joints,
infusion with a product with a more sustained therapeutic
window may reduce the risk for early re-bleeding, perhaps
altering the typical cycle of bleeding, synovial inﬂammation,
and subsequent re-bleeding. Adults using on-demand ther-
apy may already be infusing once weekly to treat their
bleeds. Once they have gained experience using a longer
acting agent once per week in this context, it may be easier
to transition them to a weekly prophylactic schedule and
avoid breakthrough bleeding.
Evaluating the Risks
Immunogenicity
There have really only been three major therapeutic
class introductions for the management of hemophilia over
the past 40 years: highly puriﬁed plasma-derived factor
concentrates, recombinant clotting factors, and the currently
explored novel bioengineered recombinant factors. Despite
many studies and meta-analyses, debate still rages over
whether there is increased immunogenicity for rFVIII [67],
which is a remarkable facsimile of the plasma-derived form.
More recently, a controversy has been discussed in the lit-
erature over whether a minimally modiﬁed bioengineered
rFVIII, B domain deleted-FVIII, exhibits increased immuno-
genicity over non-bioengineered rFVIII forms [68–71]. The
current slate of novel bioengineered clotting factors include
much more signiﬁcant modiﬁcations including fusion to
other protein sequences (Fc, albumin), and direct chemical
modiﬁcation (e.g., PEG) any of which could be new targets
for recognition by the immune system. In contrast, some of
these strategies, such as PEGylation may actually be asso-
ciated with a reduced risk for inhibitors as the hydrophilic
PEG conjugates could create a ‘‘conformational cloud’’
sterically hindering immune interactions. While the lack of
inhibitors is certainly encouraging from the early phase clin-
ical trials to date with these agents, the history in this ﬁeld
suggests this will be an ongoing area of investigation for
many years.
PEG
PEGylated products to treat a number of conditions have
been approved and safely used for 20 years in both adult
and pediatric patients [72]. In addition, PEG can be found
in many commonly used consumer products such as tooth-
paste, cleansing agents (shampoo, soap), fragrances, and
cosmetics. Nevertheless, there have also been recognized
unfavorable effects. These can include hypersensitivity
reactions, either to the polymer itself or by-products formed
during synthesis. These often occur through complement
activation and can provoke anaphylactic shock. Pre-existing
IgG and IgM anti-PEG antibodies were identiﬁed in over
25% of healthy donors and anti-PEG antibodies were
induced in some patients within a clinical trial for PEG-as-
paraginase [73]. Anti-PEG antibodies have also been
strongly correlated to rapid clearance of PEG conjugates
[74]. Another disadvantage is that PEG is non-biodegrad-
able and excretion relies on urine and stool elimination
which occurs very slowly. The fate of PEG at the cellular
level, particularly the liver and other reticuloendothelial
organs, needs further investigation. There are no system-
atic long-term studies that clearly show whether PEG is
excreted completely, if it is partly retained where it accumu-
lates, and what the potential effects are at those sites of
accumulation. For a therapeutic that will potentially be
delivered weekly or more often over the life of a person
with hemophilia, these are important issues.
Future Directions
Though several of these half-life extension strategies
could eventually satisfy regulatory bodies for approval,
there is plenty of room for continued innovation. Alternative
delivery vehicles for FVIII that would not rely on VWF asso-
ciation for plasma stability could help overcome the limita-
tions in FVIII half-life extension that have been observed.
Alternatively, modiﬁed forms of rFVIII with enhanced VWF
association, such as single chain forms as has been
explored recently [75], could provide an incremental
increase in plasma half-life. Novel indirect strategies to pro-
long FVIII half-life could include co-infusion with a bioengi-
neered rVWF with extended half-life. In addition, if the cur-
rent longer-acting factors were partnered with any of the
non-protein therapies such as the TFPI inhibitors, the he-
mostatic protection could be further enhanced at the tail
end of the pharmacokinetic curve when plasma levels have
reached minimally hemostatic concentrations. This could
conceivably push the dosing intervals for longer-acting FVIII
closer to weekly dosing and much longer for longer-acting
FIX, perhaps realizing a therapeutic regimen that is much
closer to that used for FXIII replacement. Alternatively,
these agents may allow for much more aggressive prophy-
lactic regimens targeting trough levels that are much higher
to better manage surgery, target joints, or facilitate more
active lifestyles. Despite some caution as we enter this new
era of hemophilia management, the prospects for the future
have never been brighter.
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